You have 9 free searches left this month | to do more

venetoclax

Venetoclax is a drug used to treat Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and other conditions. Venetoclax is being actively studied in 216 studies and prior, has been studied in 19.

Top SponsorsTop SitesTop Investigators
AbbVieM D Anderson Cancer CenterMatthew S. Davids, MD
M.D. Anderson Cancer CenterMD Anderson Cancer CenterPaolo Ghia
Hoffmann-La RocheDana Farber Cancer InstituteAndrew Lane
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Not yet recruiting
  • Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  • (no location specified)
2021-09-16
Sep 16, 2021
D
Safe Accelerated Venetoclax Escalation in CLL
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Venetoclax
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-09-08
Sep 8, 2021
N
Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax
  • Taipei, Taiwan
    National Taiwan University Hospital
2020-11-03
Nov 3, 2020
N
Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia
Recruiting
  • Chronic Lymphocytic Leukemia
  • Venetoclax
  • Taipei, Taiwan
    National Taiwan University Hospital
2020-11-02
Nov 2, 2020
H
Venetoclax Registry
Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax
  • Hannover, Niedersachsen, Germany
    Medical School Hannover
2021-02-15
Feb 15, 2021
U
Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
Not yet recruiting
  • Myeloproliferative Neoplasm
  • BCR-ABL Negative
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
2021-09-29
Sep 29, 2021
D
Copanlisib Plus Venetoclax in R/R DLBCL
Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-09-08
Sep 8, 2021
A
Expanded Access to Venetoclax
Available
  • Chronic Lymphocytic Leukemia (CLL)
  • +6 more
  • Venetoclax
  • (no location specified)
2021-05-24
May 24, 2021
K
Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma
Suspended
  • Primary CNS Lymphoma
  • Stuttgart, Baden-Württemberg, Germany
    Klinikum Stuttgart
2021-09-15
Sep 15, 2021
D
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
Recruiting
  • Leukemia
  • Venetoclax
  • Standard Chemotherapy
  • Boston, Massachusetts
  • +1 more
2021-08-02
Aug 2, 2021
H
Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening
Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax
  • Helsinki, Uusimaa, Finland
    HelsinkiUCH
2021-08-24
Aug 24, 2021
U
Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia
  • Aurora, Colorado
    Universtiy of Colorado Hospital
2021-02-19
Feb 19, 2021
D
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-03-15
Mar 15, 2021
D
Venetoclax Plus Inotuzumab for B-ALL
Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Venetoclax
  • +2 more
  • Boston, Massachusetts
  • +1 more
2021-08-28
Aug 28, 2021
U
Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia
  • Chicago, Illinois
    University Of Chicago Medicine Comprehensive Cancer Center
2021-05-12
May 12, 2021
C
Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma
Recruiting
  • Non-hodgkin Lymphoma
  • Venetoclax
  • Cleveland, Ohio
  • +1 more
2021-05-11
May 11, 2021
M
Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma
Not yet recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2021-07-27
Jul 27, 2021
U
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Edmonton, Alberta, Canada
  • +1 more
2021-05-14
May 14, 2021
D
Ibrutinib + Venetoclax in Untreated WM
Recruiting
  • Waldenstrom Macroglobulinemia
  • MYD88 Gene Mutation
  • Boston, Massachusetts
  • +1 more
2020-12-21
Dec 21, 2020
G
Study Evaluating the Safety and Effectiveness Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia (AML)
Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
2021-10-04
Oct 4, 2021
B
Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
Not yet recruiting
  • Relapsed Non Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Loncastuximab tesirine
  • Venetoclax
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cance
2021-10-05
Oct 5, 2021
D
A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome
Recruiting
  • Richter Syndrome
  • Venetoclax
  • +2 more
  • Boston, Massachusetts
  • +3 more
2021-06-21
Jun 21, 2021
M
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Recruiting
  • Acute Myeloid Leukemia
  • Boston, Massachusetts
  • +1 more
2021-06-21
Jun 21, 2021
J
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN
Recruiting
  • Acute Myeloid Leukemia (AML)
  • +4 more
  • Venetoclax
  • +3 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-07-08
Jul 8, 2021
M
Venetoclax and Ibrutinib in Treating Participants With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruiting
  • BTK Gene Mutation
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-03-29
Mar 29, 2021